Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 1, 2008, Pages 106-108

  Taketomi, Taro ^a   Szlam, Fania ^a   Levy, Jerrold H ^a   Tanaka, Kenichi A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BERIPLEX; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; DRUG EFFICACY; DRUG STABILITY; FIBRINOLYSIS; HEMOPHILIA; HUMAN; LETTER; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOELASTOGRAPHY;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DRUG INTERACTIONS; FACTOR VIIA; FIBRINOLYSIS; HUMANS; PLASMA; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; WARFARIN;

EID: 37849017372     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282f185c9     Document Type: Letter

References (13)

1. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116:619-624.
2. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Int Med 2002; 137:884-888.
3. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100:148-152.
4. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84:747-751.
5. Katori N, Tanaka KA, Szlam F, Levy JH. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100:1781-1785.
6. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75:344-349.
7. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006; 134:314-319.
8. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26:2445-2453.
9. Lisman T, de Groot PG, Lambert T, Rojkjaer R, Persson E. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003; 1:2175-2178.
10. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfusion Med Rev 1993; 7:78-83.
11. Mauser-Bunschoten EP, Koopman MMW, Goede-Bolder ADE, Leebeek FWG, van der Meer J, van Marwijk Kooij GM, et al. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002; 8:649-656.
12. Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131:1308-1314.
13. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006; 367:252-261.